Protein kinases are directly implicated in many human diseases; therefore, kinase inhibitors show great promises as new therapeutic drugs. In an effort to facilitate the screening and the characterization of kinase inhibitors, a novel application of the AlphaScreen technology was developed to monitor JNK activity from (1) purified kinase preparations and (2) endogenous kinase from cell lysates preactivated with different cytokines. The authors confirmed that both adenosine triphosphate (ATP) competitive as well as peptide-based JNK inhibitors were able to block the activity of both recombinant and HepG2 endogenous JNK activity. Using the same luminescence technique adapted for binding studies, the authors characterized peptide inhibitor mechanisms by measuring the binding affinity of the inhibitors for JNK. Because of the versatility of the technology, this cell-based JNK kinase assay could be adapted to other kinases and would represent a powerful tool to evaluate endogenous kinase activity and test a large number of potential inhibitors in a more physiologically relevant environment. (Journal of Biomolecular
INTRODUCTION

A
BOUT 500 PROTEIN KINASES are encoded in the human genome, 1 and 27 of the 291 known cancer genes encode protein kinases. 2 Recent reviews have highlighted the key roles of these protein kinases in a large number of diseases, including inflammatory (rheumatoid arthritis, multiple sclerosis, asthma, inflammatory bowel disease, and psoriasis), neurodegenerative (Alzheimer's, Parkinson's, and Huntington's diseases, stroke), metabolic (obesity and type 1 and 2 diabetes), and oncologic diseases. 3 Therefore, the pharmaceutical industry is always exploring the therapeutic potential of novel kinase inhibitors, and more than 30 kinase inhibitors are already under clinical development. However, a large number of these kinase inhibitors that target the adenosine triphosphate (ATP) binding pocket have poor specificity and affinity for their substrates. 4, 5 Moreover, most of these kinases have been characterized only in vitro, by showing an inhibition of recombinant kinases. Characterization of novel, highly specific kinase inhibitors is essential because these inhibitors should be able to block and modulate a given kinase pathway in a cell-type and response-specific fashion. Therefore, testing these inhibitors in cell cultures or directly in vivo is crucial.
AlphaScreen is a nonradioactive bead-based technology used to study biomolecular interactions in microplate formats. The acronym ALPHA stands for amplified luminescence proximity homogenous assay. It requires a biological interaction that brings "donor" and "acceptor" beads in close proximity, resulting in a cascade of chemical reactions to produce an amplified signal (see Warner et al. 6 for details of the reactions). To date, different studies have used the AlphaScreen technology to measure the activity of recombinant 6 or purified 7 kinases. The aim of this study was to develop a kinase assay able to characterize new kinase inhibitors by measuring not only the activity of recombinant kinase but also endogenous kinase in whole-cell systems. Using the AlphaScreen technology, we were able to measure in vitro the activity of recombinant c-Jun-NH2-terminal (JNK) kinase as well as the activity of stimulated endogenous JNK activity. This study details for the first time a compatible high-throughput screening (HTS) assay for a rapid, reproducible, and reliable cell-based JNK assay. Comparison of AlphaScreen with time-resolved fluorescence resonance energy transfer (TR-FRET; LANCE™) and FlashPlate ® technologies showed clearly the advantages of the AlphaScreen technology to measure recombinant or endogenous kinase activity. Although this HTS assay has been developed specifically to study JNK activity and to analyze binding properties of potential JNK inhibitors, AlphaScreen technology has been used previously to measure recombinant or purified kinase activity but should easily be adapted to quantify endogenous kinase activity playing key roles in signal transduction. This study suggests that this assay could become a key tool for the discovery and characterization of kinase-specific inhibitors.
MATERIALS AND METHODS
Materials
AlphaScreen general IgG (protein A) detection kit (#6760617), Histidine (Nickel Chelate) detection kit (#6760619), white opaque 384-well microplates (#6007390), and TopSeal-A 384 (#6005250) were purchased from PerkinElmer/Biosignal (Montreal, Québec, Canada). GST-cJun (1-79) fusion protein (#205145) was ordered from Stratagene (La Jolla, CA). Recombinant JNK3/SAPK1b active (#14-501) and anti-phospho-cJun (Ser73) antibody (#06-659) were purchased from UpState (Charlottesville, VA). Staurosporine was purchased from Sigma (#S4400; St. Louis, MO). Interleukin1-β (IL1-β) and tumor necrosis factor α (TNFα) cytokines were purchased from PeproTech or Sigma Aldrich (St. Louis, MO). Peptide inhibitors (L-Tat:
and JBDs mut: R-P-K-A-A-A-A-A-N-A-F-P-Q-V-P) were ordered from Auspep (Parkville Victoria, Australia). EZ-Link™ Biotin-BMCC (#21900) and DSalt Polyacrylamide Desalting Columns (#43240) were purchased from Pierce (Rockford, IL). AlphaScreen experiments were performed with a Fusion™ or EnVision™ Universal Microplate Analyzer, PerkinElmer (Boston, MA).
Protein and peptide biotinylation
GST-cJun fusion protein was biotinylated as described previously. Briefly, 500 µL of protein (1 mg/mL) was mixed with 500 µL of 0.1 M MES buffer, and then 2.25 µL of a 10-mg/mL solution of Biotin-BMCC was added and incubated 2 h at 37 °C. The purified proteins were desalted on a PD-10 column equilibrated in phosphate-buffered saline (PBS), 0.01% Tween-20.
was synthesized by the University of Laval (Québec, Canada), and an extra cytosine was added at the C-terminal of the peptide. Biotinylation of the modified peptide was performed using standard procedures with maleimide-PEG-biotin. Briefly, in 50 mM HEPES 7.0 and 150 mM NaCl, 200 nmol of peptide was mixed with 1 µmol of biotin-PEG-maleimide. The mixture was incubated overnight at 37 °C, and the biotinylated peptide was then purified by high-performance liquid chromatography (HPLC). Both biotinylated proteins (B-GST-cJun and B-JNKi-C) were titrated in the biotin-streptavidin AlphaScreen assay to determine the concentration of biotinylated peptide or protein recognized by the streptavidin (SA) donor beads.
Cell culture
HepG2 cells were kept in culture at 37 °C in a humidified atmosphere containing 5% CO 2 . Cells were seeded in 60-mm tissue culture dishes (10 6 cells/dish) and maintained in regular Dulbecco's modfied eagle medium (DMEM) supplemented with 10% fetal calf serum. The next day, cells were stimulated for 30 min with increasing concentrations of IL1-β and TNFα. Then, cells were lysed in buffer A (20 mM Tris acetate [pH 7.0], 0.27 M sucrose, 1 mM EDTA, 1 mM EGTA, 50 mM NaF, 1% Triton X-100, 5 mM sodium pyrophosphate, 10 mM β-glycerophosphate, 1 mM dithiothreitol) prior to being analyzed with either the traditional or the AlphaScreen kinase assay. For all-in-one well experiments, HepG2 cells were first seeded (3000 cells/well) the day before the assay; increasing concentrations of IL1-β and TNFα, diluted in DMEM-F12 (without fetal bovine serum [FBS] and red phenol), were then added (10 µL) to cells, and an incubation of 30 min at 37 °C was followed. Then, 5 µL of lysis buffer (20 mM HEPES/0.5% Tween, pH 7.4) was added to cells. Kinase inhibitors were then added at diverse concentration levels, and the AlphaScreen kinase assay was performed on these cell lysates following the protocol, described in the next section.
AlphaScreen kinase assay
Kinase reagents (B-GST-cJun, anti-P-cJun antibody, and active JNK3) were first diluted in kinase buffer (20 mM TrisHCl [pH 7.6], 10 mM MgCl2, 1 mM DTT, 100 µM Na3VO4, 0.01% Tween-20) and added to wells (15 µL). Reactions were then incubated in the presence of 10 µM of ATP for 1 h at 23 °C. Detection was performed by an addition of 10 µL of bead mix (protein A acceptor 20 µg/mL and streptavidin donor 20 µg/mL), diluted in detection buffer (20 mM Tris-HCl [pH 7.4], 20 mM NaCl, 80 mM EDTA, 0.3% bovine serum albumin [BSA]), followed by another 1-h incubation at 23 °C in the dark. For measurement of JNK endogenous activity, kinase assays were performed as described above, except that active JNK3 was replaced by cell lysates, and reaction kinase components were added after the cells lysis. B-GST-cjun and P-cJun antibody were used at the same concentrations, whereas ATP was used at 50 µM instead of 10 µM. The AlphaScreen signal was analyzed directly on the Fusion™ or EnVision™.
Binding assay
Interaction assays between active JNK3 and both biotinylated GST-cJun (B-GST-cJun) and JNKi-C (B-JNKi-C) peptide were performed in kinase buffer. Both biotinylated proteins and the His-tagged active JNK3 were incubated in 10-µL kinase buffer for 1 h at at 23 °C. For competition experiments, we added increasing concentrations of mentioned peptide inhibitors and incubated them for 1 h at 23 °C. Then we added 15 µL of bead mix (Ni 2+ acceptor 20 µg/mL and streptavidin donor 20 µg/mL) and incubated them for 1 h in the dark at 23 °C. The plate was then read on the Fusion™ or EnVision™.
Radioactive kinase assays and gel quantification
Then, 20 µg of HepG2 protein extracts, processed as described above, was incubated with 1 µg (500 nM) of GST-cJun (amino acids 1-89), coupled to glutathione-agarose beads for 3 h at 4 °C. The beads were washed 3 times with washing buffer (lysis buffer supplemented with 0.1% Triton X-100) and twice with kinase buffer (20 mM HEPES [pH 7.5], 20 mM glycerophosphate, 10 mM MgCl 2 , 1 mM DTT, 50 µM Na 3 VO 4 ). Finally, they were resuspended in kinase buffer supplemented with 5 µCi of {γ-33 P}ATP. Following incubation at 30 °C for 30 min, reaction products were separated by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis on a denaturing 10% polyacrylamide gel. Gels were stained with Coomassie blue to check for equal loading of the samples, dried, and subsequently exposed to X-ray films.
RESULTS
Description and optimization of the AlphaScreen JNK assay
The AlphaScreen technology has been developed and adapted for many assays, including quantitative assays 8 (cAMP and IP3 detection), interaction assays 9,10 (protein/protein, DNA/ protein, cytokine binding assays, and homogeneous phage display), and in vitro enzymatic assays (phosphatase, protease, and kinase). 6, 7 The JNK assay described herein measures the specific phosphorylation of the substrate cJun by the mitogen-activated protein kinase (MAPK), JNK. In this assay, cJun was produced as a GST fusion protein and labeled by the addition of a biotin molecule. The resulting biotinylated GST-cJun (B-GST-cJun) could therefore be captured by the streptavidin donor beads (Fig. 1a) . To measure the levels of B-GST-cJun phosphorylation, we used an anti-phospho-cJun antibody (anti-phosphoserine 63), which is captured by protein A-coated acceptor beads (Fig. 1a) . When B-GST-cJun was phosphorylated, either in vitro by recombinant active JNK3 or by endogenous JNKs in cells, acceptor and donor beads were brought into close proximity, leading to energy transfer measured by light emission (Fig. 1b) . In the absence of acceptor bead proximity, no signal is produced.
The primary task was to optimize the kinase assay conditions using active recombinant kinase. Based on previous AlphaScreen assay developments, 6 fixed concentrations of B-GST-cJun (10 nM), anti-phospho-cJun (30 nM), and enzyme (3 nM) were used to determine the enzyme-and substrate-apparent K m . As shown in Figure 2a ,b, the AlphaScreen signal increased in a dose-dependent manner, reaching a maximum at 10 µM ATP as well as 20 nM of substrate. The apparent K m was established at 465 nM and 2 nM for ATP and substrate, respectively. No signal was observed in the absence of JNK3. Saturating concentrations of ATP were used to further optimize the assay to allow for the evaluation of allosteric inhibitor potency, such as the JNKi peptides that interfere at the enzyme-substrate interface. We evaluated the optimal concentration of substrate using 10 µM ATP and fixed concentrations of anti-phospho-cJun (30 nM) and JNK3 (3 nM) (Fig. 2b) . The emission was maximal with 10 nM of substrate (B-GST-cJun), with a signal to background ratio (S:B) of 43.8 ± 2.4 (n = 5). When optimizing the anti-phospho-cJun antibody concentration, maximal signal was
FIG. 1.
Principle of the AlphaScreen kinase assay: the AlphaScreen kinase assay is constructed by capturing the biotinylated GST-cJun (B-GST-cJun) with streptavidin-coated donor beads. The phosphorylated form of cJun is captured by a specific anti-phospho-cJun antibody (anti-PcJun) bound to protein A-coated acceptor beads (a). Recombinant or endogenous JNK activity is measured by phosphorylation of B-GST-cJun (b). The presence of all "partners" brings donor and acceptor beads into close proximity (≤ 200 nm). Upon laser excitation at 680 nm, a fluorescent signal is produced and detected between 520 and 620 nm.
obtained at 100 nM of antibody (Fig. 2c) . However, for cost reasons, and because the S:B ratio was better at 30 nM of antibody (45.1 ± 4.7, n = 3), we chose to pursue the assay development using the latter concentration. In both substrate and antibody titration experiments, very low background signal was observed in the absence of ATP (Fig. 2b,c) . Assays performed in the absence of either the substrate or the specific antibody generated signals equivalent to background levels (data not shown). We then performed a dose-response curve using increasing JNK3 concentrations with the optimized conditions (10 µM ATP, 10 nM B-GST-cJun, and 30 nM anti-phospho-cJun antibody). To keep an optimal assay window, enzyme titration was performed using a saturating concentration of substrate. However, it should be kept in mind that the IC 50 of allosteric inhibitors could be further characterized using a different concentration of substrate. As shown in Figure 2d , the response was linear over 2 log with a Hill slope of 1.
Using a traditional pull-down radioactive kinase assay, we could detect a signal at 0.5 nM of JNK3, whereas 0.1 nM was sufficient using the AlphaScreen assay (S:B = 21.6 ± 5.3, n = 5) (Fig. 2d,e) . Moreover, higher interassay variability was observed in the radioactive kinase assay compared to the AlphaScreen assay (data not shown). The concentration of B-GST-cJun substrate required to obtain an optimal AlphaScreen assay (10 nM) was 10-to 50-fold lower than the optimal concentration used in a traditional pull-down assay, which suggests a higher sensitivity of the AlphaScreen assay.
Measurement of endogenous JNK activity
The optimized conditions determined using the in vitro assay were used to measure endogenous JNK activity from HepG2 cells following exposure to different cytokines. For comparison, the same protein lysates were used in parallel for both the AlphaScreen and the radioactive JNK assays. As shown in Figure 3a ,b, the AlphaScreen kinase assay was the most quantitative and sensitive assay format because 1000-fold less protein as well as 50-fold less substrate was required to detect a signal compared to the radioactive assay (Fig. 3c,d) .
In vitro inhibition of JNK activity
ATP competitive chemical inhibitors of various serine/ threonine kinases (SP600125 and staurosporine) and a new, specific, and cell-permeable peptide-based JNK inhibitor, JNKi, [11] [12] [13] were tested on recombinant JNK3. The L-JNKi peptide was engineered by linking the minimal 21-amino acid inhibitory domain of the islet/brain (IB1), also called the JNK interacting protein (JIP1), to the 10-amino acid HIV-TAT-derived sequence that can rapidly translocate into cells. 11 As described in Figure 4a , the 2 broad-spectrum inhibitors, SP600125 and staurosporine, blocked JNK3 activity with low efficiency. In comparison, LJNKi showed a 1000-fold better inhibition of JNK3 activity, with an IC 50 of 1 nM (Fig. 4a) . The retro-inverso D-form (see review 14 ) of JNKi, D-JNKi, was synthesized as a protease-resistant peptide and compared to L-JNKi for its potency. D-JNKi inhibited JNK3 with about 2-logarithm lower affinity than LJNKi (Fig. 4b) . Both L-Tat and D-Tat peptides, used as negative controls, did not alter cJun phosphorylation by JNK3 (Fig. 4b) . assay could be exploited for the HTS of small chemical compounds as well as for peptide-based inhibitors able to block recombinant JNK activity.
Endogenous JNK activity in whole cell
To obtain highly selective inhibitors, it is crucial to measure the inhibition in more physiological conditions. Therefore, we set up a cell-based assay and measured endogenous JNK activity in cell lysates following induction by cytokines. In this assay, we stimulated HepG2 cells with IL-1β or TNFα, lysed them, and measured JNK activity in the same well (see process flow in Fig. 5 ). In this cell-based assay, 3000 cells per well were seeded 48 h prior to being exposed for 30 min to cytokines. Measurement of JNK activity was done with 10 nM B-GST-cJun, 30 nM anti-phospho-cJun antibody, and 50 µM ATP. Maximal induction of JNK was observed at 0.1 ng/mL of IL-1β (S:B = 4.5 ± 0.05) or at 10 ng/mL of TNFα (S:B = 2.3 ± 0.03) (Fig. 6a) . A slight basal level of non-cytokine-stimulated endogenous JNK activity (without cytokines) was detected, but only background signal was observed in the absence of ATP (Fig. 6a) , B-GST-cJun substrate, and/or anti-P-cJun antibody (data not shown). As shown by the Z´ value 15 measured in the absence and presence of ATP, this assay was highly reproducible, with a Z´ value of over 0.5 and S:B = 12.3 (n = 96) (Fig. 6b) . Therefore, this assay could be adaptable to HTS.
Analysis of JNK inhibition in a cell-based assay
We then tested the effect of staurosporine and SP600125 in the cell-based assay. Both inhibitors blocked IL-1β-induced JNK activity in a range of 1 to 10 µM (Fig. 6c) . Similar IC 50 values were obtained for the inhibition of both the recombinant active JNK3 (Fig. 4a) and the endogenous JNK activated by cytokine treatment (Fig. 6c) . The values were also consistent with the ones reported in the literature. 16 We then tested different JNK peptide inhibitors derived from the JNK binding domain (JBD) sequence present in the scaffold protein IB1/ JIP1; we synthesized a shorter form of L-JNKi, called JBD small (JBDs), and a retro-inverso D-form of the peptide (DJNKi). Both L-JNKi and JBDs were the 2 most potent JNK inhibitors, whereas the D-form was less potent than the L-form (Fig. 6d) , as observed in the in vitro inhibition assay. This expected result is in accordance with in vivo observations, showing that higher concentrations of D-JNKi are needed to inhibit JNK activity with the same efficiency of L-JNKi in neuronal or pancreatic β cells (Bonny et al., personal communication, 2005) . These results together confirmed that the AlphaScreen kinase assay is able to measure endogenous kinase activity in cell lysates and represents a powerful tool to characterize JNK inhibitors in an environment that more closely reproduces physiological conditions.
HTS technologies comparison
Because other HTS technologies are currently available to detect kinase activity in vitro, we evaluated the performance of our AlphaScreen assay to 2 other HTS platforms: TR-FRET (LANCE™) and FlashPlate ® (see Fig. 7a ,b for assay principle). We were able to measure in vitro JNK activity using both technologies, but S:B ratios were smaller than the one obtained with the AlphaScreen technology. Respectively, LANCE™ and the FlashPlate ® approaches generated an S:B ratio of about 1.5 ( Fig. 7b) and 10 (Fig. 7e) . To clearly show the advantage of our AlphaScreen cell-based assay, we also compared results obtained by AlphaScreen technology with both TR-FRET (LANCE™) and FlashPlate ® technologies. We were able to measure a signal in the LANCE™ JNK assay (S:B = 1.6) after a 30-min incubation of cells with 10 ng/mL IL-1β (Fig. 7c) . On the other hand, no signal was observed with the FlashPlate ® technology (Fig. 7f) . Altogether, these results support the fact that the AlphaScreen technology is the most suitable system to measure kinase activity not only in vitro but also from whole stimulated cell lysates.
Binding properties of peptide-based JNK inhibitors
In contrast to chemical inhibitors that directly affect kinase activity by competing with the ATP-binding site, peptide-based inhibitors interfere with protein-protein interactions. To understand the mechanism behind the JNKi-based inhibition of JNK, we tested the binding of recombinant JNK3 with either the biotinylated protein substrate (B-GST-cJun) or the biotinylated JNKi peptide (B-JNKi-C). As shown by the scheme in Figure 8a , whereas Ni 2+ -coated acceptor beads captured the His-tagged JNK3, the streptavidin donor beads captured the biotinylated peptide or protein. The binding of JNK3 with either B-GST-cJun or B-JNKi-C was quantified by measuring the emission of acceptor beads at 520 to 620 nm after laser excitation at 680 nm (Fig. 8a) . Figure 8b shows that both B-GST-cJun and B-JNKi-C were able to bind the JNK3 protein kinase. Moreover, we observed higher (100-fold) affinity of JNK3 for the peptide B-JNKi-C. This observation is consistent with previous studies 17 showing that JNK has 100-fold greater affinity for IB1/JIP1 (JNKi peptide is derived from IB1/JIP1 scaffold protein) than for cJun.
In competition experiments, nonbiotinylated L-JNKi, JBDs, or JNKi-C was able to interfere with both the protein-protein and the peptide-protein interactions (Fig. 8c,d) . It is interesting to note that the presence (L-JNKi) or the absence (JNKi-C) of the Tat sequence did not affect the binding property of the JNKi peptide (Fig. 8d) . Moreover, the 8 extra residues present on the JNKi-C peptide compared to the JBDs peptide are not crucial for its binding to JNK3. No competition was observed in the presence of control peptides-i.e., L-Tat or the mutated form of JBDs (JBDs mut), where all amino acids involved in the binding of JNK were replaced by alanine residues. Interestingly, the DJNKi peptide was not able to displace the JNK3/B-JNKi-C binding to the same extent as L-JNKi, which is in agreement with less potent inhibition of the JNK3 enzymatic activity by the D-JNKi (Fig. 8d) .
DISCUSSION
To measure the activity of recombinant and endogeneous kinases, we have developed a novel nonradioactive homogeneous assay as a powerful alternative to traditional radioactive pull-down and in vitro HTS assay. The activity of JNK was used as a proof of concept, and 2 types of JNK inhibitors (i.e., ATP competitive small molecules and peptide-based inhibitors) were tested. Small chemical molecules decrease JNK activity by blocking the ATP-binding pocket of the kinase, whereas peptidebased inhibitors are able to block the interaction between the kinase (JNK) and its substrate (cJun). With the technology described herein, we were able to test both ATP analogues and peptide-based inhibitors, and we clearly showed that the second generation of JNK inhibitors (JNKi and JBDs) is more potent than the nonspecific chemical kinase inhibitors (staurosporine and SP600125).
Because of the complexity of the kinase signaling pathway in whole cells, it is crucial to test inhibitors under physiologically relevant conditions. Shults et al. 18 described recently a method, using modified fluorescent chemosensors, that could be adapted for HTS kinase assay in whole cells. This fluorescence-based strategy could be very powerful, despite the limitations of FRETbased platforms to work with full-length proteins. As a matter of fact, because the Förster critical distance for efficient energy transfer falls between 10 and 15 nm, 19 this later technology may prove less applicable to the measurement of large biomolecular interactions such as the enzyme-substrate interaction. In both the kinase and the binding AlphaScreen assays described herein, we were able to use full-length proteins reflecting the physiological conditions of interaction occurring between proteins. Moreover, Table 1 . Comparison between Traditional Radioactive Pull-down JNK Assay and JNK AlphaScreen Assay all-in-one well experiment allowed the measurement of kinase activity in a specific cell type stressed with a specific stimulus.
It is critical to optimize the nature of peptide inhibitors (i.e., length, amino acid composition, and enantiomery) to obtain cost-effective and highly specific kinase inhibitors. Therefore, using the AlphaScreen binding assay, we were able to compare different peptides (L-JNKi, D-JNKi, and JBDs) and showed that these peptide inhibitors were able to compete for both the binding of JNK3 to the cJun substrate and to the JBD region of IB1/JIP1. In a competition assay, both L-JNKi (21 A.A.) and JBDs (15 A.A.) showed the same affinity for JNK3. The JBDs peptide shares similarity with the pepJIP1 (P-K-R-P-T-T-L-N-N-F) peptide described by Heo et al. 20 Our results are consistent with their data, showing an inhibition of JNK in the range of 200 nM and a strong binding affinity of pepJIP1 for JNK1. Both AlphaScreen kinase and binding assays showed that the shorter form of the JNKi peptide is almost as effective as the peptide itself and could be profitable, for cost reasons. The more stable D-form of the JNKi peptide was 100 times less efficient than the L-JNKi at inhibiting the interaction between the JNK3 and JNKi peptide. The 2-log difference in potency observed could reflect the different ability of such drugs to affect JNK activity. The lower affinity of the D-JNKi peptide for JNK3 (Fig. 6c ) might explain the difference of inhibition observed in vitro (Fig.  4b ) and in vivo (Fig. 5d) on JNK activity.
This screening method has many advantages compared to the traditional pull-down kinase assays (see Table 1 for comparison) and to other HTS platforms. 21 Direct comparison of homogeneous time-resolved fluorescence (HTRF), time-resolved fluorescence (TRF), and AlphaScreen technologies performed in this study or previously published 22 showed that the AlphaScreen system had the highest sensitivity and dynamic range. Due to the signal amplification cascade reaction, AlphaScreen is capable of detecting molecular interactions occurring at very low concentrations (< femtomolar range). Moreover, due to the time-resolved reading mode of 20 msec delay, signal contamination by autofluorescence is virtually eliminated, leading to a limited background signal. Moreover, the emission wavelength (520-620 nm) is lower than the excitation wavelength (680 nm), which eliminates the background signal from plates or other assay components. Consequently, the combinations of strong signals and low background result in very high S:B ratios, even at very low enzyme and substrate concentrations. In addition, the measurement of JNK activity with other widely used platforms, such as TR-FRET (LANCE™) and FlashPlate ® (Fig. 8) , highlights the advantages of the AlphaScreen technology. Although we were able to monitor JNK activity with both TR-FRET and FlashPlate ® , the S:B ratio was lower and did not allow the use of such assays as cellbased kinase platforms-especially for FlashPlate ® technology, which was widely used for the characterization of new kinase inhibitors.
The strength of AlphaScreen is its ability to measure low affinity binding because each donor bead carries up to 3000 streptavidin molecules, and a single protein A-coated acceptor bead can bind up to 400 antibodies. Therefore, the binding signal is dependent not only on 1 pair of binding partners but on dozens or even hundreds of them. The AlphaScreen assay is also ideally suited for HTS because it could easily be automatable and miniaturizable. 23, 24 Finally, the AlphaScreen technology is highly versatile and could, due to the availability of relatively lowcost generic substrates and a widerange spectrum of antibodies, be adapted to a large collection of kinase assays. Moreover, we could envisage using acceptor beads coated with phosphate chelators (Bosse et al., personnal communication, 2006; Rininsland et al. 25 ), instead of protein A-coated acceptor beads and antiphospho antibody. This change could be a key point for the setup of a real platform allowing the measurement of a larger number of kinases without the need of specific phospho antibodies.
Finding specific inhibitors is a true challenge because of the large number of kinases involved in the cellular process. The homogeneous assay using cell lysates described herein would provide a powerful and essential method to screen, identify, and characterize novel and more relevant kinase inhibitors, in a biological context, that better reproduces cellular conditions. Although we demonstrated the feasibility to monitor cytokineinduced JNK activity, other pathologically interesting pathways could also be studied using the AlphaScreen cell-based assay.
